Factor XIII Deficiency Treatment Market is Projected to Reach US$ 400.7 Million by 2034, Growing at 5.8% CAGR

Increased Awareness and Diagnosis of Rare Bleeding Disorders along with Advancements in Treatment Options is driving the Market, States Fact.MR

According to Fact.MR, a market research and competitive intelligence provider, the Global Factor XIII Deficiency Treatment Market is estimated to reach a valuation of US$ 228.0 million in 2024 and is expected to grow at a CAGR of 5.8% during the forecast period of (2024 to 2034).

The growth of factor XIII deficiency treatment market can be subjected to reasons such as increased awareness among population and healthcare providers for rare bleeding disorders. The elevation in diagnosis rate and availability of treatment options are also responsible for the surge in this market. Over the past few years, various organizations and patient advocacy groups have contributed to educating the people. This increase in awareness has led to healthcare providers being able to make earlier diagnoses as more providers are aware of this rare disorder and the symptoms associated with it. There are better tools to make this diagnosis, genetic testing, and more advanced coagulation assays, which ensure quick diagnosis and treatment of the patients.

In addition to the increased awareness, the availability of better treatment options is changing how Factor XIII deficiency is managed. The introduction of new medications, especially recombinant factor XIII products, allows patients to have better tolerable and more effective treatment options than the conventional therapies which are plasma-derived. These new drugs are targeted more toward the specific deficiency than dosing and therefore reduce the incidence and severity of bleeding as well as transfusions. Most importantly, due to ongoing scientific and clinical advancements, new and encouraging treatments have been developed, which helps to build more trust between healthcare providers and patients.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=1348

Key Takeaways from the Market Study:

• The global factor XIII deficiency treatment market is projected to grow at 5.8% CAGR and reach US$ 400.7 million by 2034.
• The market created an absolute $ opportunity of US$ 172.7 million growing at a CAGR of 5.8% between 2024 and 2034.
• North America is a prominent region that is estimated to hold a market share of 35.9% in 2034.
• Companies such as Grifols, CSL Behring, Octapharma, LFB Group, and Novo Nordisk along with several blood banks are contributing in the treatment of factor XIII deficiency.
• Factor XIII concentrate which a type of replacement therapy is estimated to grow at a CAGR of 5.7% creating an absolute $ opportunity of US$ 143.2 million between 2024 and 2034.
• North America and Western Europe are expected to create an absolute $ opportunity of US$ 103.6 million collectively.
• By patient type, congenital factor XIII deficiency is more prominent in the factor XII deficiency treatment market with an estimated value of US$ 340.2 Mn in 2034.

Category-wise Insights:

Replacement therapy is expected to witness significant demand due to its proven efficacy, with the market projected to reach a value of US$ 294.9 million by 2034, growing at a CAGR of 5.9% from 2024 to 2034. The increasing adoption of replacement therapy is transforming the market for factor XIII deficiency, as healthcare professionals recognize the critical importance of timely treatment. With more cases being diagnosed, the need for effective solutions is rising, driving the demand for recombinant Factor XIII products.

These advanced therapies effectively address deficiencies, significantly reducing the risk of bleeding-related complications. Moreover, new recombinant products offer superior efficacy and a higher safety profile compared to traditional plasma-derived alternatives. They also minimize the risk of infectious disease transmission, thereby lowering complications associated with transfusions. As awareness of factor XIII deficiency grows and more patients are diagnosed, the demand for effective replacement options continues to expand, shaping the market's future growth.

Key Companies Profiled:

• Grifols
• CSL Behring
• Octapharma
• LFB Group
• Novo Nordisk
• Other Market Players

Increased Awareness and Diagnosis of Rare Bleeding Disorders:

As a result of the lack of information on factor XIII deficiency among the general public and medical practitioners, several people were not diagnosed. All the educational programs from patient groups and medical professionals have helped immensely in increasing awareness. These campaigns have promoted factor XIII deficiency as an option to be considered when symptoms of bleeding are not explained.

The technological evolution in diagnostic tests such as genetic testing and sensitive coagulation tests has also contributed significantly towards the development of this market. This has made it possible for early and accurate diagnosis of factor XIII deficiency. With the growth in the diagnosis rate, there is also a growing demand for effective treatment.

Get Customization on this Report for Specific Research Solutions:https://www.factmr.com/connectus/sample?flag=S&rep_id=1348

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the global factor XIII deficiency treatment market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study reveals essential insights on the basis of Treatment Type (Replacement Therapy (Fresh Frozen Plasma Treatment and Factor XIII Concentrate) and Supportive Treatment (Blood Transfusion and Pain Management)), Patient Type (Congenital Factor XIII Deficiency and Acquired Factor XIII Deficiency), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Blood Banks) across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East & Africa).

Check out More Related Studies Published by Fact.MR Research:

Dental diagnostic imaging equipment Outlook research reveals that the global market was valued at US$ 2 Billion in 2020, and is projected to top US$ 3 Billion by 2031, expanding at a CAGR of 6%.

The global antibiotic residue test kits market size is currently being valued at US$ 184.5 million in 2023 and is projected to reach US$ 333.4 million by 2033-end, growing at a CAGR (Compound Annual Growth Rate) of 6.1% during the forecast period from 2023 to 2033.

The global single use assemblies market is expected to reach USD 29,192 million by 2035, up from USD 5,590 million in 2024. During the forecast period (2025 to 2035), the industry is projected to expand at a CAGR of 15.6%.

The global wireless health and fitness devices market currently accounts for a valuation of US$ 370 million and is expected to reach US$ 580 million by the end of 2026

Demand for cordless personal water flossers is expected to expand at a CAGR of 7% to reach US$ 184 Million by 2031, while that of countertop personal water flossers is anticipated to progress at a CAGR of 5% over the next 10 years.

The global point of care diagnostics market size was valued at US$ 34.1 Billion in 2020, and is anticipated to surge to a valuation of US$ 66 Billion by 2028